NCT03471858

Brief Summary

To determine if mechanical labour induction can offer a safer and effective alternative to prostaglandins to women with previous caesarean section attempting trial of labour after caesarean (TOLAC).

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
44

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Aug 2019

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

March 13, 2018

Completed
8 days until next milestone

First Posted

Study publicly available on registry

March 21, 2018

Completed
1.4 years until next milestone

Study Start

First participant enrolled

August 29, 2019

Completed
3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 27, 2022

Completed
3 years until next milestone

Study Completion

Last participant's last visit for all outcomes

August 16, 2025

Completed
Last Updated

December 15, 2025

Status Verified

December 1, 2025

Enrollment Period

3 years

First QC Date

March 13, 2018

Last Update Submit

December 6, 2025

Conditions

Keywords

caesarean, uterus

Outcome Measures

Primary Outcomes (1)

  • Improvement in Bishops score

    Assess for increase in Bishops score from baseline of \<5 (Unfavourable) to \>6

    24hours

Secondary Outcomes (8)

  • Achieving active labour

    Within 24-48hours of intervention

  • Number of PGE tablets required

    Within 24-48hours of intervention

  • Number of times the foley catheter (cervical balloon) needs to be readjusted

    Within 24-48hours of intervention

  • Mode of delivery

    Within 24-48hours of intervention

  • Maternal complications

    Within 24-48hours of intervention

  • +3 more secondary outcomes

Study Arms (2)

Cervical Balloon

ACTIVE COMPARATOR

Transcervical 2-way 18 French (18F) single balloon Foley catheter, applied using a sponge-holding forceps into the cervical canal with the balloon inflated to a minimum of 30ml and maximum of 60ml with sterile water or saline \[1\]. This will be administered once during the study and will be retained for a maximum of 12 hours within the 24 hour study period.

Device: Cervical balloon

Prostaglandin

ACTIVE COMPARATOR

Prostaglandin E2 (Prostin®) 3mg tablet, placed high in the vaginal fornix. This will be administered per vaginum once in the first 6 hours; a second dose is administered at the discretion of the clinician / clinical team 6 hours after the first pessary, for a cumulative total of 6mg within the 24 hour study period.

Drug: Prostaglandins

Interventions

To assess if a cervical balloon catheter (foleys catheter) for mechanical induction of labour is comparable to prostaglandin usage for induction of labour in women who have had a previous caesarean section.

Also known as: Foley Balloon Catheter
Cervical Balloon

Prostin will be used in the control arm.

Also known as: Prostin
Prostaglandin

Eligibility Criteria

Age18 Years - 50 Years
Sexfemale(Gender-based eligibility)
Gender Eligibility DetailsPregnant females
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • Female ≥ 21 years of age at booking visit
  • previous uncomplicated lower segment caesarean section (CS)
  • Aiming for TOLAC
  • Written informed consent (and assent when applicable) obtained from subject or subject's legal representative and ability for subject to comply with the requirements of the study
  • Singleton pregnancy
  • Gestational age \>37 weeks
  • Understands risk of TOLAC
  • Eligible for induction of labour for the standard obstetric indications, including post-date or post-term pregnancies at 40-41 completed weeks of gestation
  • Unfavourable Bishop's Score ≤ 5 requiring cervical priming
  • Previous uterine surgery, including simple myomectomy, where there is no contraindication to TOLAC
  • Reactive CTG pre-induction
  • Ruptured membranes

You may not qualify if:

  • Refusal to participate
  • Women with 2 or more previous CS
  • Previous classical or lower segment vertical incision, or inverted T or J incision in the previous caesarean delivery
  • Previous uterine surgery with contra-indication to future TOLAC
  • Maternal contraindication for vaginal delivery
  • Fetal contraindication for vaginal delivery or major fetal abnormality
  • Malpresentation or cord presentation
  • Placenta praevia \<20mm from internal os
  • Chorioamnionitis
  • Antepartum haemorrhage of undetermined origin AND deemed a contraindication for TOLAC
  • Suspected fetal macrosomia (estimated weight on ultrasound \>4kg) AND deemed a contraindication for TOLAC
  • Congenital uterine abnormality
  • Multifetal pregnancy
  • Latex allergy or poorly-controlled asthma

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

National University Hospital, Singapore

Singapore, 679973, Singapore

Location

Related Publications (1)

  • Choo SN, Kanneganti A, Abdul Aziz MNDB, Loh L, Hargreaves C, Gopal V, Biswas A, Chan YH, Ismail IS, Chi C, Mattar C. MEchanical DIlatation of the Cervix-- in a Scarred uterus (MEDICS): the study protocol of a randomised controlled trial comparing a single cervical catheter balloon and prostaglandin PGE2 for cervical ripening and labour induction following caesarean delivery. BMJ Open. 2019 Nov 6;9(11):e028896. doi: 10.1136/bmjopen-2019-028896.

MeSH Terms

Conditions

Obstetric Labor Complications

Interventions

ProstaglandinsKLK15 protein, human

Condition Hierarchy (Ancestors)

Pregnancy ComplicationsFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital Diseases

Intervention Hierarchy (Ancestors)

EicosanoidsFatty Acids, UnsaturatedFatty AcidsLipidsAutacoidsInflammation MediatorsBiological Factors

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER GOV
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Medical Officer

Study Record Dates

First Submitted

March 13, 2018

First Posted

March 21, 2018

Study Start

August 29, 2019

Primary Completion

August 27, 2022

Study Completion

August 16, 2025

Last Updated

December 15, 2025

Record last verified: 2025-12

Data Sharing

IPD Sharing
Will not share

Locations